An official website of the United States government
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Trial Status: active
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of
Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil)
versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic
Colorectal Cancer(HARMONi-GI3)
Inclusion Criteria
ECOG performance status score of 0 or 1
Expected life expectancy ≥ 6 months
Patients with histologically or cytologically confirmed metastatic CRC
No prior systemic therapy for metastatic CRC
At least 1 measurable noncerebral lesion
Exclusion Criteria
Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) disease
Known BRAF V600E mutant status
Current presence of significant radiographic or clinical manifestations of gastrointestinal (GI) obstruction
Ascites requiring paracentesis within last 30 days
Patients who have received prior immunotherapy or anti-angiogenic therapy for colorectal cancer
Active or prior history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)
Resectable disease
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07228832.
